Trazodone Pregnancy Category
The FDA pregnancy category system for trazodone has been discontinued and replaced with detailed narrative labeling, but trazodone was historically not assigned a formal letter category and current FDA labeling indicates no established drug-associated risks of major birth defects, miscarriage, or adverse maternal/fetal outcomes based on decades of human data 1.
Current FDA Classification Status
The old FDA pregnancy letter category system (A, B, C, D, X) was phased out in 2015 and replaced with the Pregnancy and Lactation Labeling Rule (PLLR), which requires detailed narrative descriptions instead of letter categories 2. Trazodone's current FDA labeling does not assign a letter category but provides comprehensive risk information 1.
Risk Assessment Based on FDA Drug Label
According to the most recent FDA-approved labeling 1:
Human Data
- Published prospective cohort studies, case series, and case reports over several decades have not identified any drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
- All available studies have methodological limitations including small sample size and inconsistent comparator groups
- While studies cannot definitively establish absence of risk, the available human data is reassuring
Animal Data
- Increased fetal resorption and adverse fetal effects in rats at 7.3-11 times the maximum recommended human dose (MRHD)
- Increased congenital anomalies in rabbits at 7.3-22 times the MRHD
- No teratogenic effects at doses up to 450 mg/kg/day during organogenesis
Background Risk
- The estimated background risk in the U.S. general population is 2-4% for major birth defects and 15-20% for miscarriage in clinically recognized pregnancies
Clinical Decision-Making Framework
When considering trazodone use in pregnancy, weigh the risk of untreated depression against potential fetal risks 1:
- Women who discontinued antidepressants during pregnancy were more likely to experience relapse of major depression compared to those who continued treatment
- Untreated depression during pregnancy is associated with premature birth and decreased initiation of breastfeeding 3
Recent Systematic Review Findings
A 2025 systematic review of 14 studies found 4:
- No consistent evidence linking trazodone to increased risks of congenital malformations, stillbirths, or low birth weight
- Possible association with increased risk of spontaneous and therapeutic abortions (requires further investigation)
- Limited and varied data necessitates larger, well-controlled studies
Historical Context
If the old FDA system were still in use, trazodone would likely have been classified as Category C based on the animal data showing adverse effects at high doses and the absence of adequate controlled studies in pregnant women 2. However, this is speculative since trazodone was never formally assigned a letter category in widely available references.
Practical Recommendations
- Register patients in the National Pregnancy Registry for Antidepressants (1-844-405-6185) 1
- Consider the maternal benefit of treating depression versus the theoretical fetal risk
- The decades of human experience without identified teratogenic signals is reassuring
- Do not abruptly discontinue if already taking during pregnancy; discuss tapering with careful risk-benefit analysis
Important Caveat
The absence of a formal FDA pregnancy category does not mean trazodone is unsafe—it reflects the transition to a more nuanced, narrative-based labeling system that provides clinicians with detailed information rather than oversimplified letter categories 1.